Type of transmittal letter and questionnaire color as two variables influencing response rates in a mail survey.

Mailed questionnaires to 2,123 members of a national professional organization. A significantly greater number (p     

Interferon-alpha treatment of Beh?et's disease

OBJECTIVE: To determine if interferon-alpha (IFN-alpha) is effective in Beh?et's disease (BD). METHODS: Ten patients having active BD were entered into a 6 month open label trial of IFN-alpha therapy given by self-administered dose of 3 million units subcutaneously daily. Provision was made for downward or upward dosing depending on predetermined responses. Four study centers followed the same protocol. Patients having ocular or neurologic inflammation at onset of the study were excluded. RESULTS: Seven patients completed the trial, while 3 were removed at 3 and 4 months for side effects or lack of efficacy. There was a substantial reduction in the number of oral and genital ulcers, cutaneous lesions, and articular signs and symptoms by the end of the study. Pain scores, global assessments, and prednisone dose also declined. The IFN-alpha dose at end of study averaged 1.5 million units. Significant side effects, besides the anticipated flu-like syndrome experienced by all the patients, included single instances of seizure, psychosis, psoriasis, and hyperthyroidism. CONCLUSION: The results suggest that IFN-alpha is effective therapy for some manifestations of Beh?et's disease.     

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides

OBJECTIVE: Restricted T cell receptor (TCR) gene usage has been demonstrated in animal models of autoimmune disease and has resulted in the successful use of TCR peptide therapy in animal studies. This clinical trial was undertaken to determine the safety and efficacy of a combination of Vbeta3, Vbeta14, and Vbeta17 TCR peptides in Freund's incomplete adjuvant (IFA) in patients with rheumatoid arthritis (RA). METHODS: A double-blind, placebo-controlled, multicenter, phase II clinical trial was undertaken using IR501 therapeutic vaccine, which consists of a combination of 3 peptides derived from TCRs (Vbeta3, Vbeta14, and Vbeta17) in IFA. A total of 99 patients with active RA received either 90 microg (n = 31) or 300 microg (n = 35) of IR501 or IFA alone (n = 33) as a control. The study medication and placebo were administered as a single intramuscular injection (1 ml) at weeks 0, 4, 8, and 20. RESULTS: Treatment with IR501 was safe and well tolerated. None of the patients discontinued the trial because of treatment-related adverse events. Efficacy was measured according to the American College of Rheumatology 20% improvement criteria. Using these criteria, patients in both IR501 dosage groups showed improvement in disease activity. In the most conservative analysis used to evaluate efficacy, an intent-to-treat analysis including all patients who enrolled, the 90-microg dosage group showed a statistically significant improvement compared with control patients at the 20-week time point after the third injection. Trends toward improvement were shown in both the 90-microg and the 300-microg dosage groups at week 24 after the fourth injection. CONCLUSION: IR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic, and demonstrated clinical improvement in RA patients. Additional clinical trials are planned to confirm and extend these observations.     

Temporal facilitation and stroboscopic motion.

Luminance of extended-duration adapting field was varied from zero to a level sufficient to reduce brightness of a 5 ms test stimulus to a level just above increment threshold. Increasing the luminance of surrounds or solid adapting fields resulted in increased reaction time. With the perceived-order method, reduction of latency with increasing surround luminance (temporal facilitation) was obtained with a visual comparison stimulus but not with an auditory comparison. It was concluded that perceived motion is a necessary condition for temporal facilitation. This study and earlier studies using moving test stimuli may be explained by a shift from sustained to transient units with increasing adapting luminance.     

Two transitions and two crises in youth: A response to P. S. Fry's "Changes in youth's attitudes toward authority."

In a critical discussion of P. S. Fry's (1976) studies, a discussion of psychoanalytic theory's failure to account for the increase of negative attitudes toward authority during the early phase of the identity process is presented. An alternative developmental schema is proposed as more appropriate. (PsycINFO Database Record (c) 2010 APA, all rights reserved)